We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Siemens Healthineers Demonstrates Power of Data with Atellica Diagnostics IT Solutions

By LabMedica International staff writers
Posted on 05 Aug 2019
Siemens Healthineers (Erlangen, Germany) demonstrated the power of leveraging data to unlock a laboratory’s full potential by showcasing its Atellica Diagnostics IT portfolio at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo. More...
At AACC 2019, the company featured its innovative IT solutions to combat the laboratory’s staffing challenges, limited budgets, and the increasing complexity in sample management and testing.

The Siemens Healthineers Atellica Diagnostics IT portfolio enables laboratories to unlock their full potential by leveraging data to optimize workflows. With easy-to-navigate user interfaces and centralized management of operations, the robust software solution enhances visibility into valuable business analytics that unify sample, process, result, and inventory data. These features have enabled laboratories to achieve a 93% reduction in testing errors, an 85% increase in patient and staff satisfaction, and an 88% achievement rate for 30-minute STAT turnaround.

The Atellica portfolio pipeline includes the Atellica Asa Application, a tablet-based virtual assistant designed to simplify and organize operator interactions with the instruments. The goal of the Atellica Asa Application is to draw staff attention to a single interface with only the most common, yet critical, procedures needed to complete daily system operations. The tile-based software is designed to organize operator tasks by workflow and to reduce the number of screens used to complete a single task.

In addition to demonstrations of the Atellica Asa virtual assistant, attendees learned more about LifeNet, an online program that helps labs increase system utilization by providing a centralized platform to schedule system maintenance and view service history of connected Siemens Healthineers systems. Attendees also explored the artificial intelligence-driven Guardian Program, which can help to predict certain system failures up to 21 days before they happen. By monitoring more than 80 critical components in real time, the Guardian Program can continuously detect potential issues and schedule repairs at a time that will not affect turnaround time, maintaining workflow during peak hours. Visitors to the Siemens Healthineers booth also experienced their own virtual reality journey through a simulated hospital environment to visualize in vitro testing and workflow possibilities based upon tailored needs.

Additionally, Siemens Healthineers unveiled its newest technology for point-of-care testing—the RAPIDPoint 500e Blood Gas System—for product demonstration at the event.

“Point-of-care testing enables clinicians to deliver the right test in the right setting for their patients at the right time,” said Christoph Pedain, PhD, Head of Point-of-Care Diagnostics, Siemens Healthineers.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.